Smart Extendin-4 Delivery Device Promising for Type 2 Diabetes

Share this content:
Smart Extendin-4 Delivery Device Promising for Type 2 Diabetes
Smart Extendin-4 Delivery Device Promising for Type 2 Diabetes

TUESDAY, Jan. 2, 2018 (HealthDay News) -- A smart extendin-4 (Ex4) delivery device is a promising therapeutic option for type 2 diabetes that can provide safe, long-term, and on-demand Ex4 therapy, according to a study published online Nov. 24 in Nature Communications.

Noting that delivery of therapeutic peptides for diabetes therapy is compromised by short half-lives of drugs, Wei Chen, Ph.D., from Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues examined the role of a smart Ex4 delivery device based on microneedle (MN)-array patches integrated with dual mineralized particles that separately contain Ex4 and glucose oxidase (GOx) for diabetes therapy.

The researchers found that as a result of the differential response to the microenvironment induced by biological stimuli, the dual mineralized particle-based system can specifically release Ex4 while immobilizing GOx. Thereby the system allows glucose-responsive and closed-loop release to significantly improve the therapeutic performance of Ex4. The mechanical strength of alginate-based MN can be enhanced by integration of mineralized particles by crosslinking to facilitate skin penetration, supporting transdermal administration that is painless and noninvasive.

"We believe this smart glucose-responsive Ex4 delivery holds great promise for type 2 diabetes therapy by providing safe, long-term, and on-demand Ex4 therapy," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

High Uptake, Acceptability of Rapid Fentanyl Test Strips

High Uptake, Acceptability of Rapid Fentanyl Test Strips

Significant link between receiving positive results, reporting positive change in overdose risk behavior

ACR: Walking Each Day May Cut Risk for TKA Over Five Years

ACR: Walking Each Day May Cut Risk for ...

Replacing 5 minutes of non-walking time with 5 minutes of moderate-to-vigorous walking beneficial

Short Respiratory Event Duration Ups Mortality Risk in OSA

Short Respiratory Event Duration Ups Mortality Risk in ...

Individuals with shortest-duration events had adjusted hazard ratio of 1.31 for all-cause mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »